Drug major Lupin on Thursday said it has received a warning letter from the US health regulator for its Mandideep facility in Madhya Pradesh.
This is subsequent to an earlier intimation received from the United States Food and Drug Administration (USFDA) in March 2019 wherein the agency had classified its inspection conducted at the said facility in December 2018 as "official action indicated", Lupin said in a regulatory filing.
Lupin said there are no drug master file and abbreviated new drug applications (ANDA) pending review or approval from the Mandideep (Unit-1) facility and the company does not "believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility".
also read
- Indian pharma industry has a strong growth trajectory
- Three employees of Noida-based pharma firm arrested in relation to Uzbekistan cough syrup deaths
- Central, state teams to inspect Chennai plant after Global Pharma recalls eye drops in US
- Separate funds for R&D, formulation, API: What pharma sector expects from Union Budget 2023
"We are committed to addressing the concerns raised by the USFDA and will work with the regulator to resolve these issues at the earliest," Lupin added.
Shares of Lupin were trading 1.36 per cent lower at Rs 749.15 apiece on the BSE.
